Fullscreen

  • Shorter Injectable-containing MDR/RR-TB Regimen: Pre-treatment evaluation and follow-up​

    Content

    The table below provides the details about the clinical evaluation and laboratory tests that need to be done during Pre-treatment Evaluation (PTE) to initiate patients on shorter injectable-containing Multidrug-resistant (MDR)/ Rifampicin-resistant Tuberculosis (RR-TB) regimens.

     

    Table: Clinical evaluation and laboratory tests to be done during PTE for initiation of shorter injectable-containing MDR/ RR-TB regimen; Source: Guidelines for PMDT in India-2021, p48 and 50.​
    CLINICAL EVALUATION LABORATORY-BASED EVALUATION
    History and physical examination Random Blood Sugar (RBS)​
    Height check HIV testing following counselling​
    Weight check Complete blood count (haemoglobin (Hb), Total Leucocyte Count (TLC), Differential Leucocyte Count (DLC), platelet count)​
    Psychiatric evaluation, if required Liver function tests (including serum proteins)​
      Thyroid-stimulating Hormone (TSH) levels​
      Urine examination – routine and microscopic
      Serum creatinine
      Audiometry
      Urine pregnancy test (in women of reproductive age)
      Chest X-ray
      Electrocardiogram (ECG)​

     

    Follow-up Investigations

     

    • Audiometry: Baseline and then every 2 months till Second-line Injectable (SLI) (Kanamycin (Km)/ Amikacin (Am)) course is completed and then, as and when clinically indicated 
    • Serum creatinine: Baseline and then monthly till SLI course is completed.

     

    The rest of the management would be the same as for shorter all oral Bedaquiline (Bdq) - containing MDR/ RR-TB regimen.

     

     

    Resources

     

     

    Kindly provide your valuable feedback on the page to the link provided HERE